| Filed On | Filing |
|---|---|
| 22 Oct 2026 | SCHEDULE 13D/A |
| 22 Oct 2026 | SCHEDULE 13D/A |
| 22 Oct 2026 | SCHEDULE 13D/A |
| 21 Oct 2026 | SCHEDULE 13D/A |
| 20 Oct 2026 |
8-K: Other Events
On October 16, 2026, the Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended. In connection with the closing of t... |
| 05 Oct 2026 | S-8 |
| 30 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
Reference is made to that certain Stock Purchase Agreement, dated September 8, 2026 (the “Agreement”), by and between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pag... |
| 10 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR REGISTERED OR QUALIFIED UNDER THE SECURITIES LAWS OF ANY STATE OR FOREIGN JURISDICTION OR APPROVED OR DISAPPRO... |
| 08 Sep 2026 |
8-K/A: Entry into a Material Definitive Agreement
On August 28, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into an Amended and Restated At the Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), which amends and restates in it... |
| 04 Sep 2026 | 424B5 |
| 04 Sep 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 01 Sep 2026 | 8-K: Entry into a Material Definitive Agreement |
| 31 Aug 2026 | 424B5 |
| 26 Aug 2026 | 424B3 |
| 25 Aug 2026 | EFFECT |
| 17 Aug 2026 | S-3 |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition; Submission of Matters to a Vote of Security Holders |
| 17 Jul 2026 | EFFECT |
| 16 Jul 2026 |
Proxy statement: annual meeting on August 10, 2026
CEO pay $2.2M, up 90% |
Loading...
